Lumark (lutetium (177Lu) chloride)
- Region
- 🇪🇺 EU
- Active substance
- lutetium (177Lu) chloride
- Company
- I.D.B. Radiopharmacy B.V.
- Status
- Withdrawn
- Therapeutic area
- Radionuclide Imaging
- CHMP opinion
- Wed 22 Apr 2015
- EU approval
- Thu 18 Jun 2015
- Application
- EMEA/H/C/002749
- ATC
- V10
- Official record
- www.ema.europa.eu
Indication
Lumark is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Theralugand Authorised · Eckert & Ziegler Radiopharma GmbH
- 🇪🇺 EndolucinBeta Authorised · ITM Medical Isotopes GmbH
- 🇪🇺 Ilumira Authorised · Shine Europe B.V.
- 🇪🇺 Lutetium (177Lu) chloride Billev (previously Illuzyce) Authorised · Billev Pharma Aps
Follow Lumark
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.